Semaglutide, also known as Ozempic, is a glucagon-like peptide-1 (GLP-1) receptor agonist and has emerged as a promising therapeutic agent beyond its initial use for type 2 diabetes and obesity. Recent studies have highlighted its potential in reversing non-alcoholic fatty liver disease (NAFLD) and offering significant benefits for patients with chronic kidney disease (CKD.
NAFLD, also known as metabolic dysfunction-associated steatotic liver disease (MASLD), affects approximately one in five individuals globally. Characterized by excessive fat accumulation in the liver unrelated to alcohol consumption, NAFLD can progress to more severe conditions like non-alcoholic steatohepatitis (NASH), cirrhosis, and liver cancer.
Some estimates are that up to 93% of North Americans are now considered metabolically unhealthy, an absolutely frightening statistic. Metabolic health is typically assessed based on factors such as blood pressure, blood sugar levels, cholesterol levels, body weight, and the absence of cardiovascular disease. The same 2022 study noted worsening trends in key areas like obesity and blood glucose levels over the past two decades.
A recent trial conducted by King’s College London involving 800 patients demonstrated that semaglutide significantly reduces liver inflammation and fat accumulation. After 18 months of treatment, 63% of participants experienced improvements in liver health, with notable reductions in liver enzymes and nearly 11% body weight loss.
In the SEMA-NASH study, the highest dose of semaglutide (0.4 mg daily) led to NASH resolution in 59% of patients without worsening fibrosis, compared to 17% in the placebo group. Additionally, patients experienced an average weight loss of 13%.
Chronic Kidney Disease (CKD) is a prevalent condition, especially among individuals with type 2 diabetes, leading to increased risks of kidney failure, cardiovascular events, and mortality. Semaglutide has shown promise in mitigating these risks.
The FLOW trial, a landmark study involving 3,533 patients with type 2 diabetes and CKD, found that semaglutide reduced the risk of major kidney disease events by 24% compared to placebo. These events included kidney failure, significant declines in kidney function, and death from kidney-related or cardiovascular causes.
In recognition of these benefits, the U.S. Food and Drug Administration (FDA) approved semaglutide (marketed as Ozempic) for reducing the risk of kidney disease progression in adults with type 2 diabetes and CKD.
Notably, semaglutide’s renal benefits extend beyond diabetic populations. A randomized controlled trial involving 101 overweight or obese patients with CKD but without diabetes demonstrated that semaglutide reduced urinary albumin-to-creatinine ratio (UACR) by 52%, indicating decreased kidney stress. Participants also experienced significant weight loss, averaging 9.1 kg.
Just as we are starting to discover the huge power of Semaglutide and Tirzepatide to help end the metabolic syndrome epidemic, the FDA, in league with big pharma, is ending people’s affordable access to these drugs by hamstringing the compounding labs and pharmacies in the US.
During the shortages of Semaglutide and Tirzepatide in 2022, the FDA permitted compounding pharmacies to produce these medications under specific conditions. This was a temporary measure to address supply constraints. However, with the supposed stabilization of the drug supply, the FDA is phasing out these allowances.
Shortages remain in spite of what the FDA is saying, and people who desperately need help from these drugs are now forced to buy them at up to USD 1000 per month. So if you are poor, you get to stay sick. Metabolic syndrome and obesity are represented in much higher numbers in economically disadvantaged people so this is particularly criminal in my humble opinion.
This is the official FDA Ruling for shutting down the supply of affordable GLPs:
Tirzepatide (Mounjaro, Zepbound):
State-licensed pharmacies (Section 503A): Compounding ceased on February 18, 2025.
Outsourcing facilities (Section 503B): Compounding ceased on March 19, 2025.
Semaglutide (Ozempic, Wegovy):
State-licensed pharmacies (Section 503A): Compounding ceased on April 22, 2025.
Outsourcing facilities (Section 503B): Compounding must cease by May 22, 2025, or upon a district court ruling on a pending injunction, whichever occurs first.
Pharmacies: Compounding pharmacies must adhere to the new deadlines to avoid regulatory actions.
Here in Cabo San Lucas we are fortunate we can still legally obtain our compounded versions of Ozempic and Tirzepatide at reasonable prices through a licensed physician.
While semaglutide offers significant therapeutic benefits, it is essential to consider potential side effects. Common adverse effects include gastrointestinal symptoms such as nausea, vomiting, and diarrhea. In rare cases, more severe complications like pancreatitis may occur. Patients should be monitored regularly, and therapy should be tailored to individual needs and tolerability.
This is why I recommend you get your semaglutide through a licensed doctor while here in Los Cabos, (or via Televisit) and not zoom into the pharmacy and get it. For one thing, there is fake Ozempic being sold here in Los Cabos. For another thing its super expensive! We are lucky to have compounded GLPs still available here in Cabo San Lucas.
The doctor I recommend here is taking very careful measures to ensure my referrals for compounded Semaglutide and Tirzepatide are being properly screened and dosed correctly. I recommend you use him and not trust an uneducated pharmacy worker to help you.
As always, please feel free to contact me at ro*************@ya***.com or whatsapp +526242119435.